Table 1 Baseline characteristics
|  | Training set (N = 230, %) | Validation set (N = 58, %) | P |
|---|---|---|---|
Age (y) | Â | Â | Â |
Median, years (range) | 64 (25–91) | 62 (28–89) | 0.154 |
< 40 years, n (%) | 8 (3.5) | 5 (8.6) | 0.153 |
≥ 70 years, n (%) | 74 (32.2) | 14 (24.1) |  |
Sex | Â | Â | 0.209 |
 Male | 155 (67.4) | 34 (58.6) |  |
 Female | 75 (32.6) | 24 (41.4) |  |
Histology | Â | Â | 0.146 |
 Intestinal type | 143 (62.1) | 42 (72.4) |  |
 Diffuse type* | 87 (37.8) | 16 (27.6) |  |
Clinical settings | Â | Â | 0.835 |
 Initially metastatic disease | 154 (67.0) | 38 (65.6) |  |
 Recurrent disease | 76 (33.0) | 20 (34.5) |  |
Prior gastrectomy | 120 (52.2) | 26 (44.8) | 0.353 |
Prior trastuzumab use | 40 (17.4) | 8 (13.8) | 0.511 |
Duration of prior 1st -line fluoropyrimidine plus platinum– based chemotherapy |  |  | 0.508 |
 < 3 months | 57 (24.8) | 16 (27.6) |  |
 ≥ 6 months | 87 (37.8) | 19 (32.7) |  |